Skip to main content

Health condition · Clinically reviewed

Lung cancer, from a persistent cough to a molecularly matched treatment plan.

The UK's leading cause of cancer death - but earlier diagnosis and molecular profiling are changing what treatment can offer.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a registered UK clinician before publication.

  • 02

    Sourced from guidance

    Checked against NICE, ESMO and peer-reviewed sources you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK guidance including molecular profiling, targeted therapy and immunotherapy.

Key facts

Lung cancer at a glance.

The essentials, in plain English - what it is, the types, and how it's assessed in the UK today.

  • What it is

    A malignancy arising from lung tissue, split into two biologically distinct groups - non-small cell and small cell lung cancer.

  • UK impact

    The UK's leading cause of cancer death, despite not being the most commonly diagnosed cancer.

  • NSCLC (about 85%)

    Adenocarcinoma, squamous cell carcinoma and large cell carcinoma - each with different growth patterns and treatment routes.

  • SCLC (about 15%)

    Aggressive, fast-growing and strongly linked to smoking, with a tendency to spread early.

  • Main driver

    Tobacco smoking remains the dominant risk factor, alongside radon, asbestos and occupational carcinogens.

  • Screening

    The UK Lung Cancer Screening Programme offers targeted low-dose CT to high-risk current and ex-smokers aged 55 to 74.

Why this guide matters

Timing and typing decide the outcome.

Lung cancer outcomes hinge on catching disease early and matching treatment to tumour biology. The three points below shape everything else on this page.

  • Symptoms can be subtle at first

    A persistent cough or breathlessness is easy to dismiss - early lung cancer can also cause no symptoms at all.

  • Molecular profiling changes the plan

    Testing for EGFR, ALK, ROS1 and other driver mutations decides whether targeted therapy or immunotherapy is the better first step.

  • NSCLC and SCLC are treated differently

    The two main types follow separate treatment pathways, so getting the histology right is the first and most important step.

How the diagnosis is made

From a 2WW referral to a molecularly informed plan.

The steps a UK respiratory or oncology team will normally follow under NICE NG122, in order - so you know what to expect and why.

  1. 01

    Assessing

    Symptom review and 2WW referral

    Persistent cough, haemoptysis or weight loss triggers a two-week-wait referral under NICE NG122.

  2. 02

    Assessing

    Chest X-ray first

    Quick and widely available, though a normal film does not rule out lung cancer if suspicion remains high.

  3. 03

    Confirming

    CT chest with contrast

    Defines the size, position and local spread of any lesion and guides the next investigation.

  4. 04

    Confirming

    PET-CT staging

    Identifies distant metastases and nodal involvement not visible on CT alone - central to accurate staging.

  5. 05

    Confirming

    Bronchoscopy or CT-guided biopsy

    Obtains tissue for histology - the route depends on where the tumour sits.

  6. 06

    Preparing

    Molecular profiling

    EGFR, ALK, ROS1, KRAS G12C, MET, RET, NTRK and PD-L1 testing shapes NSCLC treatment choice.

  7. 07

    Preparing

    Specialist MDT discussion

    Every case is reviewed by a commissioned lung cancer multidisciplinary team before a plan is agreed.

Typical timeline: 2WW referral to a specialist MDT-agreed plan, usually within four to six weeks.

Symptoms

What lung cancer can look like.

A mix of respiratory and systemic symptoms - and the features that mean it's time to seek urgent assessment.

  • Persistent cough

    A cough lasting more than three weeks, or a change in a long-standing cough, is the most common presenting symptom.

  • Haemoptysis

    Coughing up blood is a strong red flag that warrants urgent chest imaging.

  • Breathlessness

    Dyspnoea on exertion, sometimes with wheeze, may reflect airway obstruction or pleural involvement.

  • Chest pain

    Dull, persistent chest or shoulder pain can indicate pleural or chest-wall invasion.

  • Unexplained weight loss

    Loss of appetite and weight loss often signal more advanced disease.

  • Finger clubbing

    A subtle but recognised sign, sometimes accompanying chronic lung disease of any cause.

  • Hoarseness

    Recurrent laryngeal nerve involvement from a tumour or nodal mass can cause a persistent hoarse voice.

  • Red flag - SVC obstruction

    Facial swelling, distended neck veins and breathlessness suggest superior vena cava obstruction - an oncological emergency.

Treatment

How lung cancer is treated in the UK.

Surgery for early disease, chemoradiotherapy for locally advanced tumours, and targeted therapy or immunotherapy guided by molecular profiling for metastatic NSCLC and SCLC.

  • Surgical resection (VATS lobectomy)

    Video-assisted resection for early-stage NSCLC, often followed by adjuvant chemotherapy or immunotherapy.

  • Chemoradiotherapy

    For locally advanced NSCLC not suitable for surgery, followed by consolidation durvalumab in selected patients.

  • Targeted therapy

    Drugs matched to a driver mutation - such as osimertinib for EGFR-mutant disease - for metastatic NSCLC.

  • Immunotherapy

    Checkpoint inhibitors, alone or with chemotherapy, based on PD-L1 expression and tumour biology.

  • Stereotactic body radiotherapy (SBRT)

    A precise, high-dose option for early-stage tumours in patients unfit for surgery.

  • Platinum-etoposide chemotherapy

    The backbone regimen for small cell lung cancer, usually combined with immunotherapy.

  • Prophylactic cranial irradiation

    Considered selectively in SCLC that has responded well to initial treatment, to reduce brain relapse.

  • Smoking cessation support

    Offered at every stage - stopping smoking improves treatment tolerance and outcomes at any point in the pathway.

What this guide is based on

The sources behind every claim on this page.

UK national guidance and specialist society standards, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your respiratory physician or oncologist knows your history and scans and can tell you which parts apply to you. If in doubt, get seen.

  • NICE. Lung cancer: diagnosis and management (NG122).

  • ESMO. Clinical Practice Guidelines for metastatic non-small-cell lung cancer.

  • ESMO. Clinical Practice Guidelines for small-cell lung cancer.

  • Roy Castle Lung Cancer Foundation. Patient information and support resources.

Red flags

When lung cancer needs urgent attention.

Most follow-up happens through routine oncology clinics. These are the situations that don't wait - and where emergency assessment is needed.

  • Superior vena cava obstruction

    Facial and neck swelling, distended veins and breathlessness needing same-day oncology assessment.

  • Massive haemoptysis

    Coughing up large volumes of blood is a medical emergency requiring immediate hospital attendance.

  • Spinal cord compression

    New back pain with leg weakness or bladder disturbance in a person with known or suspected cancer needs urgent same-day imaging.

  • Hypercalcaemia of malignancy

    Confusion, thirst and constipation can reflect a paraneoplastic rise in calcium - see our hypercalcaemia guide for detail.

  • Hyponatraemia (SIADH)

    Small cell lung cancer commonly causes SIADH, driving low sodium with confusion and seizures in severe cases.

  • Neutropenic sepsis on chemotherapy

    Fever during chemotherapy is an emergency until infection is excluded and treated.

  • New unexplained breathlessness

    Sudden dyspnoea in a patient with lung cancer may reflect pulmonary embolism, effusion or infection - all need urgent review.

  • Occupational asbestos exposure

    A history of asbestos exposure raises suspicion of mesothelioma or lung cancer - flag it clearly to your clinician.

  • Often asymptomatic early

    Early lung cancer can cause no symptoms at all, which is why the screening programme targets high-risk smokers.

Living with it

A demanding diagnosis, with real support available.

Four things that make the biggest difference during treatment - specialist support, pulmonary rehabilitation, stopping smoking and sticking with follow-up scans.

A quiet reminder

You are not managing this alone.

Lung cancer nurse specialists and patient charities exist precisely for the questions that come up between appointments.

  1. 01 Support

    Use specialist services

    Lung cancer nurse specialists and the Roy Castle Lung Cancer Foundation offer practical and emotional support throughout treatment.

  2. 02 Breathing

    Pulmonary rehabilitation helps

    Structured breathing and exercise programmes improve stamina and quality of life during and after treatment.

  3. 03 Stopping

    Quitting smoking still matters

    Stopping at any stage, even after diagnosis, improves how well the body tolerates treatment.

  4. 04 Follow-up

    Stay on the surveillance schedule

    Regular imaging after treatment catches recurrence early, when more options remain open.

Frequently asked

Everything we get asked about lung cancer.

Quick answers on types, screening, molecular testing and treatment choice.

  • What is the difference between non-small cell and small cell lung cancer?

    Non-small cell lung cancer (NSCLC) accounts for around 85% of cases and includes adenocarcinoma, squamous cell carcinoma and large cell carcinoma. Small cell lung cancer (SCLC) makes up about 15%, grows faster, spreads earlier and is strongly linked to smoking. The two are treated very differently.

  • Who is eligible for lung cancer screening in the UK?

    The UK Lung Cancer Screening Programme offers targeted low-dose CT scans to current and ex-smokers aged 55 to 74 who meet a defined risk threshold. It is being rolled out in stages across England, so eligibility depends on your local area.

  • Can non-smokers get lung cancer?

    Yes. Radon exposure, asbestos, occupational carcinogens, air pollution and family history all contribute, and a meaningful proportion of adenocarcinoma occurs in never-smokers, particularly women. Molecular testing is especially relevant in this group.

  • What does molecular profiling actually change?

    Testing for EGFR, ALK, ROS1, KRAS G12C, MET, RET, NTRK and PD-L1 identifies whether a tumour has a treatable driver mutation. This determines whether targeted therapy, immunotherapy or standard chemotherapy is the right first step for metastatic NSCLC.

  • Is lung cancer surgery always the first option?

    No. Surgery, usually VATS lobectomy, suits early-stage disease in patients fit enough for an operation. Locally advanced disease is more often managed with chemoradiotherapy, and metastatic disease with systemic treatment such as targeted therapy or immunotherapy.

  • What are paraneoplastic syndromes in lung cancer?

    These are effects caused by substances the tumour releases rather than the tumour itself - for example hypercalcaemia or SIADH-related hyponatraemia. They are more common with small cell lung cancer and can sometimes be the first sign of the disease.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.